Centessa Pharmaceuticals (NASDAQ:CNTA) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Centessa Pharmaceuticals (NASDAQ:CNTA) announced its earnings results on Monday. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.04, Zacks reports.

Centessa Pharmaceuticals Trading Down 4.9 %

CNTA stock opened at $15.81 on Wednesday. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a market cap of $2.08 billion, a price-to-earnings ratio of -10.33 and a beta of 1.54. The business has a fifty day simple moving average of $16.51 and a 200-day simple moving average of $16.43. Centessa Pharmaceuticals has a 52 week low of $7.75 and a 52 week high of $19.09.

Insider Activity

In related news, General Counsel Iqbal J. Hussain sold 6,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total value of $91,740.00. Following the transaction, the general counsel now owns 118,265 shares in the company, valued at approximately $1,808,271.85. The trade was a 4.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Gregory M. Weinhoff sold 10,000 shares of the stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $17.04, for a total value of $170,400.00. Following the transaction, the insider now owns 183,266 shares of the company’s stock, valued at approximately $3,122,852.64. This trade represents a 5.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 260,168 shares of company stock valued at $4,316,568 in the last three months. Corporate insiders own 11.59% of the company’s stock.

Analyst Ratings Changes

CNTA has been the topic of several research analyst reports. Morgan Stanley reissued an “overweight” rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. TD Cowen started coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating for the company. Finally, Guggenheim reissued a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $26.00.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.